|[October 10, 2013]
RBCC Partner n3D to Present Technology Breakthroughs to Industry Thought Leaders
NOKOMIS, Fla. --(Business Wire)--
As part of its highly successful ongoing marketing push, Rainbow Coral
Corp.'s (OTCBB: RBCC) technology partner Nano3D Biosciences (n3D) will
demonstrate its incredible new 3-D cell culturing system later this
month at a landmark conference gathering top thought leaders in cell
culture models from around the country.
Nano3D Biosciences officers are scheduled to make three presentations at
the Functional Analysis and Screening Technologies (FAST (News - Alert)) Congress in
Cambridge, Mass., on October 28-29. The presentations will be part of
the Cambridge Healthtech Institute's Second Annual Engineering
Functional 3-D Tissue Models meeting, a professional gathering of
engineers, biologists and pharmacologists that will explore the latest
insights into drug discovery and development, from designing the
bioreactors to engineering the 3-D models and utilizing drug screening
"This will be a unique opportunity for our partners to offer up
practical discussion, solutions and case studies for refining
first-stage drug discovery methods using the Bio-Assembler," said RBCC
CEO Patrick Brown. "It will be a true privilege to have our device
highlighted at this high-profile conference gathering all of the top
experts in 3D tissue engineering."
Rainbow BioSciences, RBCC's biotech subsidiary, acquired an equity
interest in n3D last year, positioning the company to participate in the
potentially impressive upside in store for n3D. Rainbow Biosciences is
ddicated to the marketing and development of new medical and research
technology innovations designed to help capture a growing share of a
booming biotech industry alongside Bristol Myers Squibb Co. (NYSE: BMY),
Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and
Amgen Inc. (NASDAQ: AMGN).
For more information on RBCC's partnership with n3D and other biotech
initiatives, please visit www.rainbowbiosciences.com/investors.html.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral
Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships
with biotechnology developers to deliver profitable new medical
technologies and innovations. For more information on our
growth-oriented business initiatives, please visit www.RainbowBioSciences.com.
For investment information and performance data on the Company, please
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This news release contains forward-looking information within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements that include the words "believes," "expects,"
"anticipate" or similar expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that
may cause the actual results, performance or achievements of the Company
to differ materially from those expressed or implied by such
forward-looking statements. In addition, description of anyone's past
success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information
included herein for events occurring after the date hereof.
[ Back To Technology News's Homepage ]